ADVANCING ORPHAN ONCOLOGY
About us
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway.
Headquarter is in Malmö, Sweden, and the company’s shares are listed on Nasdaq Stockholm (ticker: ACE)
Latest presentations
Ascelia Pharma company presentation Oct 2021 (pdf)
Q2 2021 presentation (pdf), link to webcast
…
PREVIOUS CAPITAL MARKET DAYS
Latest news
- 2021-10-19Ascelia Pharma’s Food Effect Study with Orviglance successfully completed
- 2021-09-21Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the Development of Oncoral in Combination with LONSURF®
- 2021-08-19Quarterly Report Q2 2021: Preparing Oncoral for the next level
- 2021-08-18Covid-19 extends recruitment period of SPARKLE study
- 2021-08-13Abstract for Orviglance comparison study to gadolinium accepted at the world’s largest radiology conference RSNA
Events
- October 28 @ 19:00 - 19:20
Redeye Investor Forum Malmö
- November 4 @ 08:00
Interim report 9M (January-September 2021)
- November 11
Redeye Life Science Day
- November 30 - December 2
Danske Bank’s Winter Seminar
- 2022-02-10 @ 08:00
Full year report 2021 (January-December 2021)